ICCC
NASDAQImmuCell Corporation
Website
News25/Ratings0
News · 26 weeks47+217%
2025-10-262026-04-19
Mix3190d
- Insider18(58%)
- SEC Filings8(26%)
- Earnings4(13%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Dimarco Anthony3 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 3 filed by new insider Guillemette Gilles3 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Turner Kathy V4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Tomsche David Scott4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Basse Gloria F4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Wainman Paul R4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- SECSEC Form PRE 14A filed by ImmuCell CorporationPRE 14A - IMMUCELL CORP /DE/ (0000811641) (Filer)
- INSIDERSEC Form 4 filed by Gathagan Bryan K.4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Wainman Paul R4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Tomsche David Scott4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Brockmann Bobbi Jo4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Rosgen Steven T.4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERSEC Form 4 filed by Basse Gloria F4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- SECImmuCell Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent DirectorsPORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. The Company also announced it is moving to a 7-person Board of Directors with six Independent Directors and the CEO, and that it will create a Strategy and Technology Committee of the Board of Directors. Dr. Guillemette has more than 30 years of executive experience in animal health therapeutics. He has held executive positions at
- SECImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales ResultsPORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026. Total sales for the three-month period ended March 31, 2026 were $10.4 million, a 28.4% increase compared to the three-month period ended March 31, 2025. For the three-month period ended March 31: Domestic sales were $9.7 million in 2026, a 35.7% increase compared to 2025International sales were $0.6 million in 2026, a 30.2% decline compared to 2025Tri-Shield® sales
- INSIDERSEC Form 3 filed by new insider Turner Kathy V3 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- SECSEC Form 10-K filed by ImmuCell Corporation10-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- INSIDERSEC Form 4 filed by Brigham Michael F4 - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Te Boekhorst Paul Francis Olivier4/A - IMMUCELL CORP /DE/ (0000811641) (Issuer)
- SECImmuCell Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to BoardPORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Compensation and Stock Option Committee and as a member of the Audit Committee. Ms. Turner brings more than three decades of commercial executive leadership experience in global healthcar
- SECImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)
- PRImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced its unaudited financial results for the year ended December 31, 2025. Management's Discussion: "Today we are reporting 2025 net operating income of $1.6 million, an increase of $3.3 million compared to 2024. These results were largely driven by a significant improvement in gross margin, reflecting higher volumes, manufacturing efficiencies, and price realization," commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. "Net loss